Table 1

Demographic characteristics of the patients with systemic sclerosis (SSc) and control patients with rheumatoid arthritis (RA), primary Raynaud's phenomenon (PRP), morphea as well as healthy subjects and anti-AT1R and anti-ETAR antibody levels for each group studied

SSc (N=298)Diffuse SSc (N=123)Limited SSc (N=175)RA (N=208)Primary Sjögren syndrome (N=38)PRP (N=32)Morphea (N=33)Control (N=372)
Female sex (%)83.674.889.776.997.484.481.861.9
Age (years)56.0 (54.5 to 57.5)53.5 (51.0 to 56.0)57.8 (55.9 to 59.7)58.4 (56.6 to 60.3)54.1 (49.8 to 58.4)37.0 (18.0 to 63.0)45.1 (37.0 to 53.1)46.8 (44.8 to 48.8)
Duration of disease (years)6.8 (6.0 to 7.5)6.4 (5.2 to 7.6)7.1 (6.1 to 8.1)5.9 (4.9 to 6.8)6.3 (4.2 to 8.4)7.2 (3.9 to 10.6)6.4 (4.2. to 8.6)NA
Anti-topo I antibody (% pos)27.358.25.7NA000NA
Anticentromere antibody (% pos)36.85.858.3NA000NA
Anti-U1RNP antibody (% pos)12.417.19.1NA000NA
Proven PAH (%)13.817.910.9NA0NANANA
Scleroderma renal crisis (%)5.713.80NANANANANA
Digital ulcers (%)29.946.318.3NANANANANA
Anti-AT1R antibody (units)20.5 (19.0 to 22.1)24.5 (21.8 to 27.2)17.7 (16.0 to 19.4)10.9 (10.0 to 11.8)14.4 (10.6 to 18.2)11.0 (8.6 to 13.3)11.7 (8.9 to 14.4)10.2 (8.8 to 11.6)
Anti-ETAR antibody (units)21.8 (20.3 to 23.4)25.4 (22.8 to 27.9)19.3 (17.4 to 21.2)11.2 (10.3 to 12.1)16.2 (12.3 to 20.3)11.8 (7.6 to 15.8)11.2 (7.3 to 15.0)9.5 (8.2 to 10.9)
  • Data are presented as frequency (%) or means (95% CI).

  • AT1R, angiotensin II type 1 receptor; ETAR, endothelin-1 type A receptor; NA, not applicable; PAH, pulmonary arterial hypertension.